The nuclear receptor ligand-binding domain: Structure and function

Current Opinion in Cell Biology

Volumn 10, Issue 3, 1998, Pages 384-391

  Moras, Dino ^a   Gronemeyer, Hinrich ^a  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; TRANSCRIPTION FACTOR;

CRYSTAL STRUCTURE; GENE ACTIVATION; GENE REPRESSION; LIGAND BINDING; MOLECULAR BIOLOGY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; RECEPTOR BINDING; REVIEW;

EID: 0031833450     PISSN: 09550674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-0674(98)80015-X     Document Type: Article

References (52)

1. Escriva H, Safi R, Hanni C, Langlois MC, Saumitou-Laprade P, Stehelin D, Capron A, Pierce R, Laudet V. Ligand binding was acquired during evolution of nuclear receptors. of special interest Proc Natl Acad Sci USA. 94:1997;6803-6808 This study shows that nuclear receptors are specific to metazoans and that their diversity was generated by two waves of gene duplications during evolution. The authors conclude from their study that the primordial NRs acted as 'orphan' activators or repressors which acquired ligand-binding ability during evolution.
2. Gronemeyer H, Laudet V. Nuclear Receptors. Protein Profile. 2:1995;1173-1308.
3. Gronemeyer H, Moras D. Nuclear receptors. How to finger DNA. Nature. 375:1995;190-191.
4. Göttlicher M, Heck S, Herrlich P. Transcriptional crosstalk, the second mode of steroid hormone action. J Mol Med. 1998;. in press.
5. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 270:1995;1491-1494.
6. Rochette-Egly C, Adam S, Rossignol M, Egly JM, Chambon P. Stimulation of RAR alpha activation function AF-1 through binding to the general transcription factor TFIIH and phosphorylation by CDK7. Cell. 90:1997;97-107.
7. Glass CK, Rose DW, Rosenfeld MG. Nuclear receptor coactivators. Curr Opin Cell Biol. 9:1997;222-232.
8. Wolffe AP. Transcriptional control. Sinful repression. Nature. 387:1997;16-17.
9. Pazin MJ, Kadonaga JT. What's up and down with histone deacetylation and transcription? Cell. 89:1997;325-328.
10. Beato M, Herrlich P, Schütz G. Steroid hormone receptors: many actors in search for a plot. Cell. 83:1995;851-857.
11. Kastner P, Mark M, Chambon P. Nonsteroid nuclear receptors: What are genetic studies telling us about their role in real life. Cell. 83:1995;859-869.
12. Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell. 83:1995;841-850.
13. Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, Jones SA, McKee DD, Oliver BB, Willson TM, Zetterström RH, Perlmann T, Lehmann JM. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. of outstanding interest Cell. 92:1998;73-82 Cloning and analysis of a novel nuclear receptor, PXR, which activates CYP3A gene expression in response to the binding of various natural and synthetic agonists and antagonists and is likely to be involved in the regulation of steroid metabolism.
14. Bourguet W, Ruff M, Chambon P, Gronemeyer H, Moras D. Crystal structure of the ligand-binding domain of the human nuclear receptor RXRα Nature. 375:1995;377-382.
15. Renaud JP, Rochel N, Ruff M, Vivat V, Chambon P, Gronemeyer H, Moras D. Crystal structure of the RARγ ligand-binding domain bound to all-trans retinoic acid. Nature. 378:1995;681-689.
16. Wagner RL, Apriletti JW, McGrath ME, West BL, Baxter JD, Fletterick RJ. A structural role for hormone in the thyroid hormone receptor. Nature. 378:1995;690-697.
17. Brzozowski AM, Pike ACW, Dauter Z, Hubbard RE, Bonn T, Engstrsm O, Ohman L, Greene GL, Gustafsson J-A, Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. of outstanding interest Nature. 389:1997;753-758 First crystal structure of a steroid receptor ligand-binding domain in the presence of estradiol or the AF-2 (but not AF-1) antagonist raloxifen. This study reveals that helix 12 can adopt a holo (agonist) and a distinct antagonist conformation (compare Figure 2).
18. Wurtz J-M, Bourguet W, Renaud J-P, Vivat V, Chambon P, Moras D, Gronemeyer H. A canonical structure for the ligand-binding domain of nuclear receptors. Nat Struct Biol. 3:1996;87-94. [Published erratum appears in Nat Struct Biol1996, 3:206].
19. Milburn MV, Charifson P, Lambert M, Cobb J, Wisely GB. Ligand binding and activation of PPARs - crystal structures of PPARγ [Abstract] EMBO Workshop on 'Structure and Function of Nuclear Receptors'. May 2-5,1997;. Erice, Italy.
20. Vivat V, Zechel C, Wurtz J-M, Bourguet W, Kagechika H, Umemiya H, Shudo K, Moras D, Gronemeyer H, Chambon P. A mutation mimics the ligand-induced transconformation of the retinoid X receptor. of special interest EMBO J. 16:1997;5697-5709 The identification of a constitutive RXR mutant suggests that the initial event occurring in the RXR LBD upon ligand binding is the disruption of a network of van der Waals interactions. The mutant is used to support the concept of RXR subordination, i.e., the inability of RXR to respond to cognate agonists in heterodimers with RAR, TRand VDR.
21. Voegel JJ, Heine MJS, Tini M, Vivat V, Chambon P, Gronemeyer H. The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and -independent pathways. EMBO J. 17:1998;507-519.
22. Kalkhoven E, Valentine JE, Heery DM, Parker MG. Isoforms of steroid receptor coactivator 1 differ in their ability to potentiate transcription by the oestrogen receptor. EMBO J. 17:1998;232-243.
23. Ding XF, Anderson CM, Ma H, Hong H, Uht RM, Kushner PJ, Stallcup MR. Nuclear receptor binding sites of coactivators GRIPI and SRC-1: multiple motifs with different binding specificities. Mol Endocrinol. 1998;. in press.
24. Le Douarin B, Nielsen AL, Garnier JM, Ichinose H, Jeanmougin F, Losson R, Chambon P. A possible involvement of TIF1α and TIF1β in the epigenetic control of transcription by nuclear receptors. of special interest EMBO J. 15:1996;6701-6715 Contains the first description of a NR box (a LxxLL motif which is necessary and sufficient to mediate agonist - and AF-2 integrity-dependent interaction of TIF1α with nuclear receptors) in the putative co-activator TIF1α.
25. Heery DM, Kalkhoven E, Hoare S, Parker MG. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. of special interest Nature. 387:1997;733-736 Identification of the LxxLL NR boxes of RIP140 (nine copies), SRC-1 (four copies) and CBP (two copies) which interact with different efficiencies with the ER LBD in an agonist and AF-2 integrity-dependent manner. The authors show that mutation of the four NR boxes of SRC-1 abrogates its stimulation of oestrogen-induced ER transactivation.
26. Wong J, Shi YB, Wolffe AP. Determinants of chromatin disruption and transcriptional regulation instigated by the thyroid hormone receptor: hormone-regulated chromatin disruption is not sufficient for transcriptional activation. EMBO J. 16:1997;3158-3171.
27. II250.
28. Hörlein AJ, Näär AM, Heinzel T, Torchia J, Gloss B, Kurokawa R, Ryan A, Kamei Y, Söderström M, Glass CK, Rosenfeld MG. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature. 377:1995;397-404.
29. Chen JD, Evans RM. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature. 377:1995;454-457.
30. White R, Sjoberg M, Kalkhoven E, Parker MG. Ligand-independent activation of the oestrogen receptor by mutation of a conserved tyrosine. of special interest EMBO J. 16:1997;1427-1435 The authors describe that mutations of the human estrogen receptor Tyr573 to Asp, Glu or Ala generate estrogen receptor mutants that are transcriptionally active in the absence of a ligand. They hypothesize that the mutation may disrupt interactions which arrest helix H12 in its apo position and speculate that phosphorylation of this tyrosine may have the same effect, thereby circumventing ligand control of receptor activity. Similar results are reported in Weis1996 [31].
31. Weis KE, Ekena K, Thomas JA, Lazennec G, Katzenellenbogen BS. Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. Mol Endocrinol. 10:1996;1388-1398.
32. Chen ZP, Iyer J, Bourguet W, Held P, Mioskowski C, Lebeau L, Noy N, Chambon P, Gronemeyer H. Ligand- and DNA-induced dissociation of RXR tetramers. J Mol Biol. 275:1998;55-65.
33. Vivat V, Gofflo D, Garcia T, Wurtz JM, Bourguet W, Philibert D, Gronemeyer H. Sequences in the ligand-binding domains of the human androgen and progesterone receptors which determine their distinct ligand identities. J Mol Endocrinol. 18:1997;16-147.
34. Wurtz JM, Guillot B, Moras D. 3D model of the ligand binding domain of the vitamin D nuclear receptor based on the crystal structure of holo RARγ Norman AW, Bouillon R, Thomasset M. Vitamin D, Proceedings of the Tenth Workshop on Vitamin D. 1997;165-172 University of California, Riverside, California.
35. Klaholz BP, Renaud JP, Mitschler A, Zusi C, Chambon P, Gronemeyer H, Moras D. Conformational adaptation of agonists to the human nuclear receptor RARγ of special interest Nat Struct Biol. 1998; First report of the crystal structure of an RAR isotype-specific synthetic retinoid; the comparison of the crystal structures of the LBD complexes with three natural/synthetic ligands supports the concept that the ligand-binding pocket of some nuclear receptors acts as a matrix to which the ligand adapts its confirmation.
36. 70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci USA. 93:1996;5517-5521.
37. Henttu PMA, Kalkhoven E, Parker MG. AF-2 activity and recruitment of steroid receptor coactivator 1 to the estrogen receptor depend on a lysine residue conserved in nuclear receptors. Mol Cell Biol. 17:1997;1832-1839.
38. Nichols M, Rientjes JMJ, Stewart AF. Different positioning of the ligand-binding domain helix 12 and the F domain of the estrogen receptor accounts for functional differences between agonists and antagonists. EMBO J. 17:1998;733-765.
39. Starr DB, Matsui W, Thomas JR, Yamamoto KR. Intracellular receptors use a common mechanism to interpret signalling information at response elements. Genes Dev. 10:1996;1271-1283 Description of a novel type of transcription activation-independent ligand-dependent Flp recombinase assay which reveals the initial event occurring upon ligand binding the estrogen receptor. The results demonstrate that agonists and antagonists differently position helix 12 and implicate the F region in mechanisms of antagonist action.
40. Gaub MP, Bellard M, Scheuer I, Chambon P, Sassone-Corsi P. Activation of the ovalbumin gene by the estrogen receptor involves the fos-jun complex. Cell. 63:1990;1267-1276.
41. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, Scanlan TS. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. of special interest Science. 277:1997;1508-1510 The two ER isotypes were found to transactivate differently in response to several ligands through AP1 sites, although an identical transactivation pattern was observed of a classical oestrogen response element-containing reporter. These results suggest that the two isoforms may have distinct signaling abilities in vivo.
42. Hu E, Kim JB, Darraf P, Spiegelmann BM. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARγ Science. 274:1996;2100-2103.
43. Voegel JJ, Heine MJS, Zechel C, Chambon P, Gronemeyer H. TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J. 15:1996;3667-3675.
44. Oate SA, Tsai SY, Tsai MJ, O'Malley BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science. 270:1995;1354-1357.
45. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS. AlB1, a steroid receptor coactivator amplified in breast and ovarian cancer. of outstanding interest Science. 277:1997;958-965 Identification of a nuclear receptor co-activator which belongs to the TIF2/SRC-1 family (see Figure 1a). The AlB1 gene, located on chromosome 20q12, was found amplified in 10%, and showed high expression levels in 64%, of 105 unselected primary breast tumors.
46. Li H, Gomes PJ, Don Chen J. RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2. Proc Natl Acad Sci USA. 94:1997;8479-8484.
47. Chen H, Lin RJ, Schiltz RL, Chakravarti D, Nash A, Nagy L, Privalsky ML, Nakatani Y, Evans RM. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with p/CAF and CBP/p300. Cell. 90:1997;569-580.
48. Takeshita A, Cardona GR, Koibuchi N, Suen CS, Chin WW. TRAM-1, a novel 160-kDa thyroid hormone receptor activator molecule, exhibits distinct properties from steroid coactivator-1. J Biol Chem. 272:1997;27629-27634.
49. Torchia J, Rose DW, Inostroza J, Kamei Y, Westin S, Glass CK, Rosenfeld MG. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature. 387:1997;677-684.
50. Thompson JD, Higgins DG, Gibson TJ. ClustalW: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22:1994;4673-4680.
51. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Speigelmann BM. A cold inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell. 92:1998;829-839.
52. Lefstin JA, Yamamoto KR. Allosteric effects of DNA on transcriptional regulators. Nature. 392:1998;885-888.